Affymax, Inc. is a clinical-stage drug
development company that is developing a rich pipeline of
synthetic peptide-based drugs against clinically-validated
targets for the treatment of kidney diseases and cancer.
Affymax is a recognized world leader in peptide drug
discovery, providing superior product profiles over protein
and antibody products.
